Current Liabilities (Tables)

6 Months Ended

Jun. 30, 2019

Payables and Accruals [Abstract]

Schedule of accrued expenses

Accrued expenses consisted of the following as of June 30, 2019 and December 31, 2018 (in thousands):

	June 30, 2019		December 31, 2018
Commercial rebates, fees and returns	$	107,919	$	80,520
Milestone payment for FDA approval of Vyleesi	60,000		—
Professional, license, and other fees and expenses	23,663		23,242
Salaries, bonuses, and other compensation	16,674		22,482
Research and development expense	3,311		2,226
Interest expense	867		1,067
Restructuring expense	1,777		—
Total accrued expenses	$	214,211	$	129,537